Tegafur/Gimeracil/Oteracil Potassium

替加氟/吉莫斯特/氧嗪酸钾

Report date: 2026/05/26 20:00:28

Base Information

Drug NameTegafur/Gimeracil/Oteracil Potassium
Drug Alias Nametegafur, CIDU and oxonic acid替加氟/吉美嘧啶/奥替拉西钾复方氟特嗪Tegafur - gimeracil - oteracil potassiumGimeracil/Oteracil/Tegafur +[16] 
ClassificationSmall molecules
Mechanisms of ActionThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyLiver Diseases +[14] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsPancreatic Neoplasms +[7] 
Approved Indications in ChinaStomach Neoplasms
Original Approved Country/TerritoryJapan
Original Approved Date1999/01/25
Country/TerritoryUnited StatesTaiwanGermany +[7] 
CombinationsYes TegafurGimeracilOteracil Potassium
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdNordic Group BvTaiho Pharmaceutical Co LtdTokushima Plant +[5] 
Inactive CompaniesUniversity Of TokyoAio-Studien-GgmbhHuazhong University Of Science And Technology +[14] 
Active IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsPancreatic Neoplasms +[7] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyLiver Diseases +[7] 

Other Information

ATC CodeL01BC53
Related LinksWikipediaKEGG